Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Masonic Cancer Center, University of Minnesota
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologic verification of B-cell lineage leukemia or B cell non-Hodgkin lymphoma and evidence of relapse/refractory disease with the presence of CD19 and/or CD22 by flow cytometry or immunohistochemistry of bone marrow aspirate, peripheral blood or node/tumor biopsy
Relapsed refractory disease that has failed conventional therapy and other therapies of higher priority
Karnofsky Performance status of ≥ 60% or, if less than 16 years of age, Lansky Play Score of ≥ 60 (appendix II)
Recovered from effects of prior therapy
Peripheral blast count under 50 x 10\^9/L
Adequate organ function within 14 days (30 days for cardiac and pulmonary) of treatment start
Women of childbearing potential and men should be advised and agree to practice effective methods of contraception during the course of study
Voluntary written consent with appropriate parent/guardian consent and minor information sheet for participants \< 18 years of age
You may not be if
Presence of leukemic or infectious pulmonary parenchymal disease
Presence of active CNS leukemia
Presence of any uncontrolled systemic infection
Documented uncontrolled seizure disorder- a seizure disorder controlled with medication
Active neurologic disorder - peripheral neuropathy alone does not exclude a patient
Active Hepatitis B or Hepatitis C (virus detectable by PCR)
Documented penicillin or cephalosporin allergies
Pregnant or lactating
Clareo Health | HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
